Anonymous Client H — Generic pharmaceutical company developing biosimilar portfolio ($600M revenue)
The company had selected 5 reference biologics for biosimilar development based on market size and patent expiry dates. However, the patent landscape for biologics is far more complex than for small molecules — patent thickets covering manufacturing processes, formulations, and methods of use can extend exclusivity well beyond the composition-of-matter patent. Two of the 5 reference products had recently been involved in high-profile biosimilar patent litigation, resulting in delayed launches and settlement payments.
A generic pharmaceutical company developing a biosimilar portfolio needed comprehensive patent landscape analysis and freedom-to-operate (FTO) assessment for 5 reference biologic products. They faced complex patent thicket challenges — each reference product was protected by 40-80 patents covering composition, manufacturing methods, formulations, and indications. Without a clear FTO analysis, they risked investing $200M+ in development only to face patent infringement litigation at launch.
We conducted a comprehensive patent landscape analysis across 5 reference products, identifying 300+ relevant patents, analyzing claims scope, and assessing freedom-to-operate. Our team of patent analysts and IP strategists reviewed patent claims in detail, mapped patent expiry timelines, identified design-around opportunities, and assessed litigation risk. We delivered launch timing recommendations with patent expiry mapping and FTO risk scoring.
Patent identification: Searched USPTO, EPO, and PCT databases for all patents related to 5 reference products, identifying 300+ relevant patents across composition, manufacturing, formulation, and method-of-use categories
Claims analysis: Reviewed patent claims in detail to assess scope, validity, and infringement risk for the client's biosimilar development approach
Patent expiry mapping: Built comprehensive patent expiry timelines for each reference product, including pediatric exclusivity, patent term extensions, and supplementary protection certificates
FTO risk assessment: Scored FTO risk for each reference product based on patent claims scope, remaining patent life, and design-around feasibility
Design-around analysis: Identified potential design-around strategies for manufacturing process patents, including alternative cell lines, purification methods, and formulation approaches
Litigation risk assessment: Analyzed recent biosimilar patent litigation outcomes for comparable reference products to assess litigation probability and potential outcomes
Launch timing optimization: Recommended optimal biosimilar launch timing for each reference product based on patent expiry, FTO risk, and market dynamics
We delivered a comprehensive FTO assessment for all 5 reference products. For 3 products, we confirmed clear FTO with recommended launch dates post-patent expiry. For 1 product, we identified a manufacturing process patent that required a design-around strategy (alternative purification method). For 1 product, we recommended delaying development due to a patent thicket that extended exclusivity by 4 years beyond the composition-of-matter expiry. We also identified 5 additional biosimilar opportunities with clearer FTO profiles.
Phase 1 (Weeks 1-4): Patent identification and database searches across USPTO, EPO, and PCT for 5 reference products
Phase 2 (Weeks 3-7): Claims analysis and FTO risk assessment for each patent cluster
Phase 3 (Weeks 6-10): Patent expiry mapping with launch window identification
Phase 4 (Weeks 9-12): Design-around analysis and litigation risk assessment
Phase 5 (Weeks 12-14): Final FTO report, launch timing recommendations, and IP risk mitigation strategy
| Metric | Before | After | Impact |
|---|---|---|---|
| FTO Confirmed | Unknown | 3 products (clear) | 3 biosimilars can launch on schedule post-patent expiry |
| Design-Around Required | Unknown | 1 product (manufacturing) | Alternative purification method identified, $2M additional development cost |
| Development Halted | Unknown | 1 product (patent thicket) | Avoided $40M+ development investment with 4-year exclusivity extension |
| New Opportunities Identified | 0 | 5 additional biosimilars | Expanded portfolio with clearer FTO profiles |
| Litigation Risk | Unknown | Low (for 4 of 5) | Design-around and timing strategy minimized litigation exposure |
“We were about to invest $40M in a biosimilar that had a patent thicket extending exclusivity by 4 years. Medifirm's patent analysis saved us from that mistake and redirected our investment to 5 products with clearer FTO. The $40M we saved funded 2 of the new opportunities they identified.”
VP, IP Strategy
Anonymous Client H
Forecast
4 biosimilar products with confirmed launch windows represent $1.8B cumulative market opportunity over 5 years post-patent expiry.
Every engagement starts with understanding your unique strategic challenge. Partner with Medifirm to transform data into decisions.